On July 9, 2021 Keymed Biosciences of Chengdu reported that it completed a $378.5 million Hong Kong IPO to develop its portfolio of antibody candidates (Press release, Keymed Biosciences, JUL 9, 2021, View Source [SID1234584748]). The company priced the IPO at the top end of the range, and its shares rose 28% in its first trading session. Founded in 2016, Keymed is developing nine products for autoimmune and cancer indications. It has developed an innovative antibody discovery platform consisting of monoclonal antibodies, antibody drug conjugates and bispecific antibodies that use its proprietary T cell engager bispecific antibody platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!